Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
Nonagase Y, et al. Among authors: kawakami h.
Oncotarget. 2016 Dec 20;7(51):84860-84871. doi: 10.18632/oncotarget.12743.
Oncotarget. 2016.
PMID: 27768588
Free PMC article.